Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Registration Form 2001

Dec 19, 2001

29777_rf_2001-12-19_1aa01efd-f6d7-4fc3-8c34-b611514cb7d5.zip

Registration Form

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

S-8 1 a2065093zs-8.htm S-8 Prepared by MERRILL CORPORATION QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on December 19, 2001.

Registration No. 333-

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Abbott Laboratories (Exact Name of Registrant as Specified in Its Charter)

User-specified TAGGED TABLE

Illinois 36-0698440
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)

end of user-specified TAGGED TABLE

100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of Principal Executive Offices) (Zip Code)

Abbott Laboratories Affiliate Employee Stock Purchase Plan (Full Title of the Plan)

Jose M. de Lasa Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Name and Address of Agent For Service) (847) 937-5200 (Telephone Number, Including Area Code, of Agent For Service)

CALCULATION OF REGISTRATION FEE

User-specified TAGGED TABLE

Title of Securities to be Registered(1) Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee
Common Shares (without par value) including Preferred Stock Purchase Rights 1,000,000 $54.065 $54,065,000 $12,921.54

end of user-specified TAGGED TABLE (1) In addition, this registration statement relates to such indeterminate number of additional Common Shares of the Registrant as may be issuable as a result of stock splits, stock dividends, combinations or recapitalizations, as described in the Plan. (2) The filing fee has been calculated in accordance with Rule 457(c) and (h) based on the average of the high and low prices of the Registrant's Common Shares reported on the New York Stock Exchange on December 14, 2001. ZEQ.=1,SEQ=1,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=766494,FOLIO='blank',FILE='DISK014:[01CHI9.01CHI5049]BA5049A.;6',USER='MWEINST',CD='19-DEC-2001;12:36' Generated by Merrill Corporation (www.merrillcorp.com)

TOC_END

PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference

The following documents are incorporated by reference (see, File No. 1-2189) in the registration statement:

All documents subsequently filed by the Registrant or the Plan pursuant to Section 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the registration statement and to be a part hereof from the date of filing of such documents.

Item 4. Description of Securities

Not applicable.

Item 5. Interests of Named Experts and Counsel

Brian J. Smith, Esq., Divisional Vice President and Assistant Secretary of the Registrant, whose opinion is included herewith as Exhibit 5, beneficially owned as of December 14, 2001, approximately 51,217 Common Shares of the Registrant (this amount includes approximately 20,479 shares held for the benefit of Mr. Smith in the Abbott Laboratories Stock Retirement Trust pursuant to the Abbott Laboratories Stock Retirement Plan) and held options to acquire 98,336 Common Shares of which options to purchase 72,603 Common Shares are currently exercisable.

2

ZEQ.=1,SEQ=2,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=572928,FOLIO='2',FILE='DISK014:[01CHI9.01CHI5049]JA5049A.;7',USER='MWEINST',CD='17-DEC-2001;13:29'

Item 6. Indemnification of Directors and Officers

Restated Article R-VI of the Registrant's Restated Articles of Incorporation provides that the Registrant shall, in the case of persons who are or were directors or officers of the Registrant, and may, as to certain other persons, indemnify to the fullest extent permitted by law any person who was or is a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director, officer, employee or agent of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The provisions of Article R-VI are applicable to all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding. Expenses incurred in defending a civil or criminal action, suit or proceeding may be paid by the Registrant in advance of the final disposition of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director, officer, employee or agent to repay such amount, unless it shall ultimately be determined that he/she is entitled to indemnification.

Section 8.75 of the Illinois Business Corporation Act provides that a corporation may indemnify any person who, by reason of the fact that such person is or was a director or officer of such corporation, is made (or threatened to be made) a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than one brought on behalf of the corporation, against reasonable expenses (including attorneys' fees), judgments, fines and settlement payments, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of such corporation and, in criminal actions, in addition, had no reasonable cause to believe his or her conduct was unlawful. In the case of actions on behalf of the corporation, indemnification may extend only to reasonable expenses (including attorneys' fees) and only if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, provided that no such indemnification is permitted in respect of any claim, issue or matter as to which such person is adjudged to be liable to the corporation except to the extent that the adjudicating court otherwise provides. To the extent that such person has been successful in defending any action, suit or proceeding (even one on behalf of the corporation) or in defense of any claim, issue or matter therein, such person is entitled to indemnification for reasonable expenses (including attorneys' fees) incurred by such person in connection therewith if the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation.

The indemnification provided for by the Illinois Business Corporation Act is not exclusive of any other rights of indemnification, and a corporation may maintain insurance against liabilities for which indemnification is not expressly provided by the Illinois Business Corporation Act. The Registrant's directors and officers are insured under a directors and officers liability insurance policy maintained by the Registrant.

Item 7. Exemption From Registration Claimed

Not applicable.

Item 8. Exhibits

See Exhibit Index which is incorporated herein by reference.

3

ZEQ.=2,SEQ=3,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=553963,FOLIO='3',FILE='DISK014:[01CHI9.01CHI5049]JA5049A.;7',USER='MWEINST',CD='17-DEC-2001;13:29'

Item 9. Undertakings

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

provided, however , that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-3, Form S-8 or Form F-3, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions referred to under Item 6, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

4

ZEQ.=3,SEQ=4,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=178218,FOLIO='4',FILE='DISK014:[01CHI9.01CHI5049]JA5049A.;7',USER='MWEINST',CD='17-DEC-2001;13:29' Generated by Merrill Corporation (www.merrillcorp.com)

TOC_END

SIGNATURES

THE REGISTRANT. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in unincorporated Lake County, State of Illinois on this 18th day of December, 2001.

User-specified TAGGED TABLE

ABBOTT LABORATORIES
By: /s/ MILES D. WHITE Miles D. White Chairman of the Board and Chief Executive Officer

end of user-specified TAGGED TABLE

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Miles D. White and Jose M. de Lasa, Esq., and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstititution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

5

ZEQ.=1,SEQ=5,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=198586,FOLIO='5',FILE='DISK014:[01CHI9.01CHI5049]JC5049A.;11',USER='MWEINST',CD='17-DEC-2001;13:34'

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

User-specified TAGGED TABLE

Name Title Date
/s/ MILES D. WHITE Miles D. White Chairman of the Board, Chief Executive Officer, and Director December 18, 2001
/s/ RICHARD A. GONZALEZ Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group, and Director December 18, 2001
/s/ JEFFREY M. LEIDEN Jeffrey M. Leiden President and Chief Operating Officer, Pharmaceutical Products Group, and Director December 18, 2001
/s/ THOMAS C. FREYMAN Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer (Principal Financial Officer) December 18, 2001
/s/ GREG W. LINDER Greg W. Linder Vice President and Controller (Principal Accounting Officer) December 18, 2001
/s/ ROXANNE S. AUSTIN Roxanne S. Austin Director December 18, 2001
/s/ H. LAURANCE FULLER H. Laurance Fuller Director December 18, 2001
/s/ JACK M. GREENBERG Jack M. Greenberg Director December 18, 2001
/s/ DAVID A. JONES David A. Jones Director December 18, 2001

insert table folio

6

ZEQ.=2,SEQ=6,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=774012,FOLIO='6',FILE='DISK014:[01CHI9.01CHI5049]JC5049A.;11',USER='MWEINST',CD='17-DEC-2001;13:34' end of table folio

/s/ DAVID A. L. OWEN David A. L. Owen Director December 18, 2001
/s/ BOONE POWELL, JR. Boone Powell, Jr. Director December 18, 2001
/s/ A. BARRY RAND A. Barry Rand Director December 18, 2001
/s/ W. ANN REYNOLDS W. Ann Reynolds Director December 18, 2001
/s/ ROY S. ROBERTS Roy S. Roberts Director December 18, 2001
/s/ WILLIAM D. SMITHBURG William D. Smithburg Director December 18, 2001
/s/ JOHN R. WALTER John R. Walter Director December 18, 2001

end of user-specified TAGGED TABLE

7

ZEQ.=3,SEQ=7,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=435513,FOLIO='7',FILE='DISK014:[01CHI9.01CHI5049]JC5049A.;11',USER='MWEINST',CD='17-DEC-2001;13:34' Generated by Merrill Corporation (www.merrillcorp.com) TOC_END

EXHIBIT INDEX

User-specified TAGGED TABLE

Exhibit No. Description
5. Opinion of Brian J. Smith
23.1 Consent of Arthur Andersen LLP.
23.2 Consent of Deloitte & Touche GmbH.
23.3 Consent of Ernst & Young.
23.4 Consent of Asahi & Co.
23.5 The consent of counsel, Brian J. Smith, is included in his opinion.
24 Power of Attorney is included on the signature page.

end of user-specified TAGGED TABLE ZEQ.=1,SEQ=8,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1",CHK=658943,FOLIO='blank',FILE='DISK014:[01CHI9.01CHI5049]KA5049A.;3',USER='VSTEFAN',CD='15-DEC-2001;02:39' Generated by Merrill Corporation (www.merrillcorp.com)

QuickLinks

TOC_BEGIN PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

TOC_BEGIN SIGNATURES POWER OF ATTORNEY TOC_BEGIN EXHIBIT INDEX SEQ=,FILE='QUICKLINK',USER=SLYUBOM,SEQ=,EFW="2065093",CP="ABBOTT LABORATORIES",DN="1" TOCEXISTFLAG